Sales improved from KEUR 38,870 to KEUR 43,940 (+13.0%). In the first three months. The international share of total business volume was 47.2% (3M-2020: 48.1%) and amounted to KEUR 20,728 compared to KEUR 18,679 (3M-2020). The consolidation of RVC Medical contributed about 5 % to the growth of the NEXUS Group.

The consolidated surplus rose very sharply by 25.8% to KEUR 3,820 (3M-2020: KEUR 3,037), and consolidated earnings before interest and taxes (EBIT) rose by 16.5% to KEUR 5,049 (3M-2020: KEUR 4,335). EBITA increased by 15.4% from KEUR 5,290 (3M-2020) to KEUR 6,105, and EBITDA increased by 7.9% to KEUR 9,086 (3M-2020: KEUR 8,419).

Operative cash flow, which rose from KEUR 20,204 to KEUR 20,489 in the first three months of 2021  
(3M-2020: +1.4%), was thus roughly at the same level as in the previous year and remains very high. As of 31/03/2021, the company had cash resources at its disposal in the amount of KEUR 43,804 (31/12/2020: KEUR 28,177). Nexus AG had equity capital amounting to KEUR 126,452 as of 31/03/2021 (31/12/2020: KEUR 123,583). Consequently, the equity capital rate is 50.4% (31/12/2020: 55.4%). This demonstrates that Nexus AG has a sustainable and healthy balance sheet as well as sufficient capital for further financing of its European growth strategy.

The detailed Quarterly Report Q1 can be found on our homepage at:           
https://en-en.nexus-ag.de/company/investor-relations